

RESPONSE and REMARKS

In response to the Restriction Requirement dated November 25, 2003, Applicants hereby elect Group I, drawn to nucleic acid, vector, host cell and a recombinant method to make the polypeptide of SEQ ID NO:2 (claims 1-11). Applicant hereby elects Group I without prejudice to Applicant's right to pursue the non-elected subject matter in other applications. Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups II-VIII in this or subsequent applications.

Non-elected claims 12-43 are herein cancelled. Claim 4 has been amended. No new matter is entered by virtue of the amendment. Support for the amendments lies throughout the specification, including, e.g., at page 26, lines 4-18.

This paper is being filed timely and it is believe no fees or extensions of time are required. In the event any fees or extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

23 December 2003

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-551-3676
Facsimile - 617-551-8820